Leave a Reply

Your email address will not be published. Required fields are marked *

Next Post

Trial results reveal that long-acting injectable cabotegravir as PrEP is highly effective in preventing HIV acquisition in women

Mon Nov 9 , 2020
The HIV Prevention Trials Network study (HPTN 084) on the safety and efficacy of the long-acting injectable antiretroviral drug cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected women, was stopped early by the trial Data and Safety Monitoring Board (DSMB) as results showed CAB LA to be highly effective […]

Breaking News

Recent Posts